New Approach Methodologies (NAMs) Archives

Guide

A Guide to the FDA Announcement to Phase Out Animal Testing for Drugs

The FDA is phasing out animal testing of new drugs. Learn how Certara’s Non-Animal Navigator™…

CertaraNovember 17, 2025

Announcement

Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs

Certara’s new survey findings show that 50% of Americans are unaware of FDA and NIH…

CertaraNovember 12, 2025

Publication

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

Immunogenicity poses a significant challenge in biotherapeutics development due to the formation of anti-drug antibodies…

Danielle PillsburyNovember 7, 2025

Press Coverage

Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research

The article, "Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research," explores a…

Danielle PillsburySeptember 10, 2025

Press Coverage

AI-driven drug discovery picks up as FDA pushes to reduce animal testing

AI is revolutionizing drug discovery and safety testing as drug developers adopt these technologies in…

CertaraSeptember 9, 2025

On-Demand Webinar

Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

CertaraJuly 29, 2025

Blog

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

CertaraJuly 25, 2025

Press Coverage

The end of animal testing? Transitioning to models is promising — but no silver bullet

The FDA has stated that the pharma industry must transition to using in vitro assays,…

CertaraJuly 21, 2025

Press Coverage

The Medicine Maker: The Biosimulation Generation

The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…

Danielle PillsburyJuly 1, 2025

Fact Sheet

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Certara’s Non-Animal Navigator™ solution helps companies adapt by selecting and optimizing the best-fit NAM strategies.

CertaraApril 30, 2025

New Approach Methodologies (NAMs)

A Guide to the FDA Announcement to Phase Out Animal Testing for Drugs

Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research

AI-driven drug discovery picks up as FDA pushes to reduce animal testing

Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

The end of animal testing? Transitioning to models is promising — but no silver bullet

The Medicine Maker: The Biosimulation Generation

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Newsletter sign up

Quick links

Solutions

Contact